TG Therapeutics – Consensus Indicates Potential 41.8% Upside

Broker Ratings

TG Therapeutics with ticker code (TGTX) have now 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 78 and 63 and has a mean target at 68.14. Now with the previous closing price of 48.05 this is indicating there is a potential upside of 41.8%. The day 50 moving average is 51.26 and the 200 day MA is 31.86. The market cap for the company is $6,652m. Company Website: http://www.tgtherapeutics.com

TG Therapeutics, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various treatments for B-cell malignancies and autoimmune diseases. The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. Its lead therapies include Umbralisib, an investigational dual inhibitor of PI3K delta and CK1 epsilon is being evaluated in phase 2b and phase 3 trials in patients with non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL); and Ublituximab, an investigational glycoengineered monoclonal antibody that targets a epitope on CD20-expressing B cells for patients with NHL, CLL, and relapsing forms of multiple sclerosis. In addition, the company develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. It is also has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics is headquartered in New York, New York.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index